Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y
Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red blood cells
Met primary efficacy endpoint demonstrating non-inferiority of INTERCEPT Red Blood Cells (RBCs) to conventional RBCs by adjusted hemoglobin increment
Primary safety endpoints:
No statistically significant
Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call
Cerus Corporation (NASDAQ:CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026
Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y
Raising Lower End of 2026 Product Revenue Guidance: Range now $229 to $231 million;
Raising 2026 IFC
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call
Cerus Corporation (NASDAQ:CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in
Refinancing extends maturity and lowers cost of capital
Enhances financial flexibility and positions Cerus to drive sustainable growth
Anticipated annual cash interest expense savings of up to $3.5 million
Cerus
Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ:CERS) ("Cerus" or the "Company"), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026
First Quarter 2026 Total Revenue of $59.9 million, Up 23% Over Prior Year; First Quarter 2026 Product Revenue of $53.7 million, Up 24% Over Prior Year
Raising Full Year Product Revenue Guidance Range to $227 million -
Cerus Corporation (NASDAQ:CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call
William "Obi" Greenman to become Executive Chairman
Leadership changes to take effect July 1, 2026
Cerus Corporation (NASDAQ:CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be
2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024
Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational
Cerus Corporation (NASDAQ:CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST.
A live
